Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company’s pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities. Despite near-term losses, consensus sees sharp EPS gains by 2028; upcoming clinical readouts and FDA decisions are key catalysts for the stock.

Since my first BUY report on Mirum Pharmaceuticals (MIRM), the stock is up 188%. Priced at $43 at the time, I argued that the investment was warranted because: The company had a portfolio of